HTG EdgeSeq PATH Assay

The HTG EdgeSeq PATH Assay (previously referred to as project Mercury) has been designed for retrospective gene expression profiling to complement traditional immunohistochemistry (IHC) testing by allowing investigators to assess mRNA expression of large numbers of biomarkers when formalin-fixed, paraffin-embedded (FFPE) sample availability is limited. The assay is designed to detect up to 470 mRNA targets, typically assessed by IHC.

Features and Benefits

  • Simultaneous, quantitative detection of 470 transcripts:
    
including those typically assessed by IHC
  • Extraction-free:
    
reduce extraction-associated data bias and sample loss
  • Reliable, reproducible performance:

    from a FFPE needle core biopsy section

Potential Applications

Measure gene expression levels with the HTG EdgeSeq PATH Assay that can assess 470 genes using a 5 µm FFPE tissue section.  This assay can:

  • Serve as a complement to IHC interpretation of results
  • Provide additional information when sample amount is limited 

Resources

HTG EdgeSeq PATH Assay sales sheet

HTG EdgeSeq PATH Assay gene list

 

Website Section: 
 

Last updated: 05/10/2017 - 14:31